← Oncology Approval Tracker

FDA DECISION ·

Rezurock

belumosudil · Kadmon Pharmaceuticals

FDA approvalNew therapyChronic graft-versus-host disease
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children age 12 and older with chronic graft-versus-host disease after failure of at least two prior systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

The approval adds a ROCK2 inhibitor for refractory post-transplant disease.

What research teams should watch

Document prior systemic treatments and baseline organ involvement before following response.

PRIMARY RECORDS

Sources